40,025 Shares in Mural Oncology plc (NASDAQ:MURA) Bought by Virtu Financial LLC

Virtu Financial LLC bought a new stake in shares of Mural Oncology plc (NASDAQ:MURA) in the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor bought 40,025 shares of the company’s stock, valued at approximately $129,000. Virtu Financial LLC owned about 0.24% of Mural Oncology as of its most recent SEC filing.

Other hedge funds and other institutional investors have also modified their holdings of the company. FMR LLC raised its holdings in Mural Oncology by 124.7% during the 3rd quarter. FMR LLC now owns 20,580 shares of the company’s stock worth $64,000 after buying an additional 11,423 shares during the period. Raymond James Financial Inc. acquired a new stake in shares of Mural Oncology during the fourth quarter valued at approximately $181,000. Point72 Asset Management L.P. purchased a new stake in shares of Mural Oncology in the 3rd quarter valued at approximately $340,000. Finally, Geode Capital Management LLC lifted its position in shares of Mural Oncology by 2.6% in the 3rd quarter. Geode Capital Management LLC now owns 190,056 shares of the company’s stock valued at $595,000 after acquiring an additional 4,731 shares in the last quarter. Institutional investors and hedge funds own 80.21% of the company’s stock.

Mural Oncology Price Performance

Shares of NASDAQ MURA opened at $1.18 on Monday. Mural Oncology plc has a one year low of $1.12 and a one year high of $5.02. The business’s 50-day moving average price is $3.72 and its two-hundred day moving average price is $3.58. The company has a market capitalization of $20.33 million, a P/E ratio of -0.13 and a beta of 3.66.

Mural Oncology (NASDAQ:MURA) last released its quarterly earnings data on Tuesday, March 11th. The company reported ($2.01) EPS for the quarter, missing analysts’ consensus estimates of ($1.96) by ($0.05). During the same period in the previous year, the business posted ($3.57) earnings per share. On average, equities analysts anticipate that Mural Oncology plc will post -7.54 EPS for the current year.

Wall Street Analyst Weigh In

Several analysts have issued reports on MURA shares. Raymond James downgraded shares of Mural Oncology from a “strong-buy” rating to an “outperform” rating and set a $18.00 target price on the stock. in a research note on Tuesday, March 25th. Jones Trading reissued a “hold” rating on shares of Mural Oncology in a research report on Tuesday, March 25th. Morgan Stanley lowered Mural Oncology from an “overweight” rating to an “equal weight” rating in a research report on Tuesday, March 25th. Finally, HC Wainwright dropped their target price on Mural Oncology from $18.00 to $6.00 and set a “buy” rating on the stock in a report on Wednesday, March 26th. Two equities research analysts have rated the stock with a hold rating and three have assigned a buy rating to the company. According to MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus target price of $13.00.

Mural Oncology Company Profile

Mural Oncology plc, a clinical-stage oncology company, focuses on discovering and developing immunotherapies for the treatment of patients with cancer. The company's lead product candidate includes nemvaleukin alfa for the treatment of mucosal melanoma as a monotherapy and platinum-resistant ovarian cancer in combination with pembrolizumab.